Interactive and Dominant Effects of Residues 128 and 141 on Cyclic Nucleotide and DNA Bindings in Escherichia coli cAMP Receptor Protein*

Xiaodong ChengDagger and J. Ching Lee§

From the Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch at Galveston, Galveston, Texas 77555-1055

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The molecular events in the cAMP-induced allosteric activation of cAMP receptor protein (CRP) involve interfacial communications between subunits and domains. However, the roles of intersubunit and interdomain interactions in defining the selectivity of cAMP against other cyclic nucleotides and cooperativity in ligand binding are still not known. Natural occurring CRP mutants with different phenotypes were employed to address these issues. Thermodynamic analyses of subunit association, protein stability, and cAMP and DNA binding as well as conformational studies of the mutants and wild-type CRPs lead to an identification of the apparently dominant roles of residues 128 and 141 in the cAMP-modulated DNA binding activity of CRP. Serine 128 and the C-helix were implicated as playing a critical role in modulating negative cooperativity of cyclic nucleotide binding. A correlation was established between a weak affinity for subunit assembly and the relaxation of cyclic nucleotide selectivity in the G141Q and S128A/G141Q mutants. These results imply that intersubunit interaction is important for cyclic nucleotide discrimination in CRP. The double mutant S128A/G141Q, constructed from two single mutations of S128A and G141Q, which exhibit opposite phenotypic characteristics of CRP- and CRP*, respectively, assumes a CRP* phenotype and has biochemical properties similar to those of the G141Q mutant. These observations suggest that mutation G141Q exerts a dominant effect over mutation S128A and that the subunit realignment induced by the G141Q mutation can override the local structural disruption created by mutation S128A.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The expression of many genes involved in different cellular functions in Escherichia coli is regulated by cAMP receptor protein (CRP)1 and cAMP (1-3). The molecular events associated with the allosteric activation of CRP are characterized by negative cooperativity in cAMP binding and a differentiation among the various cyclic nucleotides present in the cell. Although the CRP-cAMP system has served as a paradigm of transcriptional regulation in procaryotes for many years, an understanding of this allosteric activation event at the structural level is still missing.

CRP is a 47,238-Da protein made up of two identical subunits, each of which is composed of two domains connected by a hinge region. The small carboxyl-terminal domain contains a helix-turn-helix DNA binding motif. The large amino-terminal domain is responsible for cyclic nucleotide binding (4). Biochemical and biophysical evidences show that binding of cAMP allosterically induces CRP to assume a conformation that exhibits a high affinity for specific DNA sequences (5-13). However, a comparison between the active, monoliganded CRP and apo-CRP shows no significant secondary structural changes. The only observable major structural changes are associated with the doubly liganded CRP (11-16). These observations imply that conformational changes during CRP activation most likely involve rigid body movements between subunits and domains without major structural changes or a change in the dynamics of various structural elements without any significant conversion of secondary structures. In CRP these rigid body movements can be envisioned as subunit realignment and domain rearrangement that are mediated by interactions involving the subunit and domain interfaces, respectively. It has been shown that various locations in the CRP molecule all respond quantitatively to the binding of cAMP (17). These observations demonstrate that CRP responds to the binding of cAMP in a global manner. A global conformational switch is consistent with the proposed mechanisms involving either subunit realignment and domain rearrangement or a change in structural dynamics.

There is still no information to identify the structural elements in CRP that are responsible for imposing negative cooperativity in cAMP binding. How does CRP differentiate among the various cyclic nucleotides? What structural element is responsible for establishing a tight coupling between intersubunit and interdomain interactions? CRP mutants generated by site-specific mutagenesis are employed to address these outstanding issues. Studies of point mutations at residue 128 show that serine 128 is not vital for interdomain communication but plays an important role in mediating the interactions between the two subunits (18). In a recent study of mutation at residue 141, it was shown that the Gly right-arrow Gln mutation differentially perturbs the two interfacial interactions (19, 20). Structural and functional studies reveal that the G141Q mutant assumes a conformation state that has a realigned subunit interface. The G141Q mutant does not bind to specific DNA sequence without cyclic nucleotide (19). Complete activation of the mutant requires binding of cyclic nucleotide, which induces the reorientation of domains (20).

In this study, the role of residue 141 in defining cyclic nucleotide specificity and the mutual influence of residues 128 and 141 in the allosteric control of CRP toward binding to specific DNA are addressed. The in vivo and in vitro functional properties of mutant CRPs were monitored, with special attention to the subunit and domain interactions in CRP.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Chymotrypsin A and cGMP were purchased from Boehringer Mannheim. A mutagenesis kit (Altered Sites in vitro Mutagenesis System) was obtained from Promega, and a sequencing kit (Sequenase version 2.0) was from U.S. Biochemical Corp. Subtilisin (protease type XXVII) and cAMP were purchased from Sigma. Ultrapure guanidine HCl was a product of ICN Biochemical. MacConkey agar, bactotryptone, and yeast extract were obtained from Difco. CPM, fluorescein 5-isothiocyanate, and IAF were purchased from Molecular Probes. Oligonucleotides were synthesized by Genosys. Restriction endonucleases were from Promega, Life Technologies, Inc., U.S. Biochemical Corp., or Boehringer Mannheim.

Bacterial Strains and Plasmids-- A detailed description of the source and identity of the various bacterial strains and plasmids can be found in Cheng et al. (18).

Methods-- All experiments, except as specifically indicated, were conducted in buffer A (50 mM Tris, 0.1 M KCl, and 1 mM EDTA, pH 7.8). The concentration of protein, cyclic nucleotides, and fluorescence probes was determined by absorption spectroscopy using the following absorption coefficients: 20,400 M-1 cm-1 at 278 nm for CRP monomer (21); 14,650 M-1 cm-1 at 259 nm and 12,950 M-1 cm-1 at 254 nm for cAMP and cGMP (22), respectively; 30,000 M-1 cm-1 at 387 nm for CPM (23); 70,800 M-1 cm-1 at 494 nm for fluorescein (24).

Site-directed Mutagenesis-- The G141Q point mutation was generated as described previously (18-20). For constructing the double mutant S128A/G141Q, the G141Q crp gene was subcloned into the unrepaired pALTER-1 vector. The same protocol described above was then used for the second round of mutagenesis. With the new Promega Altered Sites II in vitro Mutagenesis System, multiple rounds of mutation can be introduced into the same gene without subcloning.

Lac Operon Activation in Vivo-- To test the effects of mutation on the lac operon expression, E. coli CA8445/pPRK248cIts, transformed with plasmid pPLc28 that contains the appropriate crp mutant gene, was streaked on MacConkey lactose indicator plates in the absence or presence of 0.5 mM cAMP or cGMP. The plates were incubated at 37 °C overnight. The fermentation response of the mutant was scored according to the color of the colonies on the plates. A CRP+ phenotype displays purple colonies only in the presence of cAMP, while a CRP* phenotype is defined as an amino acid substitution that yields purple colonies on MacConkey lactose plate (Lac+) in the absence of external cAMP or in the presence of cGMP. A CRP- phenotype is a mutant that always shows white colonies (Lac-) on MacConkey plates.

Protein Purification-- Wild type CRP was purified from temperature-induced E. coli K12 Delta H1/pPlcCRP1 cells grown in LB (17). Mutant CRP was isolated from E. coli CA8445/PPRK248CIts harboring plasmid PPLC28, which encodes the appropriate mutant crp gene. All CRP mutants were purified to more than 95% purity using the same protocol for wild type CRP purification (18).

Circular Dichroism-- CD spectra of wild type and mutant CRP were measured with an Aviv 62 DS circular dichroism spectrometer. To acquire a full range of near- and far-UV CD spectra, fused quartz cuvettes with path lengths of 0.01 (220-190 nm), 0.1 (270-200 nm), and 1 cm (360-240 nm) and protein solutions with concentrations of about 1 mg/ml were used. Each spectrum was recorded with a 0.5-nm increment and 1-s interval. For each sample, five repetitive scans were obtained and averaged.

Proteolytic Digestion-- Proteolytic digestion of CRP was employed as a tool to monitor the conformational changes in CRP using a previously described protocol (17, 18).

Fluorescence Labeling of CRP-- IAF modification of the wild type and mutant CRPs was carried out in 50 mM Tris, 0.3 M KCl, 1 mM EDTA at pH 7.8 in the dark. 1.1 mg/ml CRP was modified by 0.5 mM IAF at 4 °C overnight for wild type CRP and 30-45 min at room temperature for G141Q and S128A/G141Q mutants. Labeled CRP was purified by Sephadex G-25 spin columns and dialyzed extensively against buffer A. The extent of modification was determined as described previously (16, 25).

Labeling of DNA with Fluorescent Probe-- The DNA used for studying CRP-DNA interactions is the 40-base pair fragment of the lac promoter with the sequence of 5'-CAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCC-3'. The underlined sequence is the primary binding site for CRP. Complementary strands of this fragment were synthesized and purified separately by denaturing polyacrylamide gel electrophoresis. One of the single-stranded polynucleotides was then labeled with CPM at the 5'-end as described previously (26, 27). Modified single-strand DNA was hybridized with an equal amount of its complementary strand to give the fluorescently labeled double-stranded DNA. A small aliquot of the hybridization product was analyzed by nondenaturing polyacrylamide gel electrophoresis to ensure that all of the DNA was in the double-stranded form.

cAMP Binding Assays-- cAMP binding to CRP was measured by monitoring the fluorescence signal change of CRP-IAF (lambda ex = 495 nm, lambda em = 520 nm). The basic protocol employed has been previously described (17) with a minor modification (18).

CRP exists as a dimer in solution and can bind to two molecules of cAMP per dimer. Therefore, all cyclic nucleotide binding data in this study can be fitted to the following equation by a nonlinear least squares procedure to yield thermodynamic parameters K1, K2, Delta 1, and Delta 2 (17),
&Dgr;<SUB><UP>obs</UP></SUB>=<FR><NU>&Dgr;<SUB>1</SUB>K<SUB>1</SUB>[<UP>cAMP</UP>]+&Dgr;<SUB>2</SUB>K<SUB>2</SUB>[<UP>cAMP</UP>]<SUP>2</SUP></NU><DE>1+K<SUB>1</SUB>[<UP>cAMP</UP>]+K<SUB>2</SUB>[<UP>cAMP</UP>]<SUP>2</SUP></DE></FR> (Eq. 1)
where Delta obs, Delta 1, and Delta 2 are the values of change in fluorescence intensity and the normalized values of change in going from free CRP to CRP-cAMP1 and CRP-cAMP2, respectively; K1 and K2 are Adair constants for the formation of CRP-cAMP1 and CRP-cAMP2; and [cAMP] is the free cAMP concentration.

DNA Binding Study-- Fluorescence anisotropy measurements were used for quantitative measurements of CRP-DNA interactions using a previously published protocol (17).

The measured anisotropy data were fit to Eq. 2 as described previously (26) to give the apparent association constant (K) for CRP-DNA interaction according to a simple reaction scheme: P + DNA ⇆K P-DNA,
A=A<SUB><UP>D</UP></SUB>+ (Eq. 2)
(A<SUB><UP>PD</UP></SUB>−A<SUB><UP>D</UP></SUB>)<FR><NU>KD<SUB><UP>T</UP></SUB>+KP<SUB><UP>T</UP></SUB>+1−<RAD><RCD>(KD<SUB><UP>T</UP></SUB>+KP<SUB><UP>T</UP></SUB>+1)<SUP>2</SUP>−4K<SUP>2</SUP>D<SUB><UP>T</UP></SUB>P<SUB><UP>T</UP></SUB></RCD></RAD></NU><DE>2KD<SUB><UP>T</UP></SUB></DE></FR>
where A is the measured value of anisotropy; AD and APD are values of anisotropy associated with free DNA and CRP-DNA complex, respectively; and DT and PT are the total concentration of DNA and protein, respectively.

However, free CRP does not bind specific DNA, and binding of CRP to DNA in the presence of cAMP follows a more complex scheme (Scheme 1).
<AR><R><C><UP>P</UP>+<UP>2cAMP </UP> <LIM><OP><ARROW>⇄</ARROW></OP><UL>K<SUB>1</SUB></UL></LIM> </C><C><UP>P-cAMP</UP><SUB>1</SUB>+<UP>cAMP</UP></C><C> <LIM><OP><ARROW>⇄</ARROW></OP><UL>K<SUB>2</SUB></UL></LIM> </C><C><UP>P-cAMP</UP><SUB>2</SUB></C></R><R><C></C><C> +</C><C></C><C>+</C></R><R><C></C><C><UP> DNA</UP></C><C></C><C><UP>DNA</UP></C></R><R><C></C><C> ⇅K<SUB>3</SUB></C><C></C><C>⇅K<SUB>4</SUB></C></R><R><C></C><C><UP>DNA-P-cAMP</UP><SUB>1</SUB>+<UP>cAMP</UP></C><C> <LIM><OP><ARROW>⇄</ARROW></OP><UL>K<SUB>5</SUB></UL></LIM></C><C> <UP>DNA-P-cAMP</UP><SUB>2</SUB></C></R></AR>
<UP><SC>Scheme</SC> 1</UP>

Therefore, the apparent DNA binding affinity of CRP (K) is a function of cAMP concentration, which in accordance to the above scheme can be expressed as follows.
K=<FR><NU>K<SUB>1</SUB>K<SUB>3</SUB>[<UP>cAMP</UP>]+K<SUB>1</SUB>K<SUB>2</SUB>K<SUB>4</SUB>[<UP>cAMP</UP>]<SUP>2</SUP></NU><DE>1+K<SUB>1</SUB>[<UP>cAMP</UP>]+K<SUB>1</SUB>K<SUB>2</SUB>[<UP>cAMP</UP>]<SUP>2</SUP></DE></FR> (Eq. 3)
K1 and K2 can be determined independently from the cAMP binding assay. The binding affinity of CRP-cAMP2 (K4) is very weak and can not be precisely determined (17). However, the apparent DNA binding affinity of the CRP in the presence of 100-200 µM cAMP, where most of the CRP exists in the monoliganded form, has been shown to be a good estimation of the intrinsic DNA binding affinity of the CRP-cAMP1 complex (28). Therefore, in this study the apparent DNA affinity of CRP in the presence of 200 µM cAMP was assumed to represent K3.

Sedimentation Equilibrium-- The quaternary structure of CRP was monitored by sedimentation equilibrium as described previously (29). Experiments were conducted in a Beckman-Spinco model E analytical ultracentrifuge equipped with a photoelectric scanner, an electronic speed control, and an RTIC temperature control. The high speed, meniscus depletion procedure was employed (30). The loading CRP concentrations were between 0.2 and 0.4 mg/ml. Sedimentation data were acquired (10 scans) and then averaged after reaching equilibrium. The density of the solution was determined with a Mettler-Paar Precision DMA-02D density meter. Values of the partial specific volume of the wild type and mutant CRPs in native buffer and 6.0 M GuHCl were calculated based on the amino acid composition of CRP (31, 32) using the procedure of Cohn and Edsall (33) and Lee and Timasheff (34), respectively.

Sedimentation equilibrium data were fit by nonlinear least squares to a dimer assembly scheme according to the equation,
C=&Dgr;C+<UP>exp</UP>[<UP>ln</UP>C<SUB>0</SUB>&sfgr;(r<SUP>2</SUP>/2−r<SUP>2</SUP><SUB>0</SUB>/2)] (Eq. 4)
+<UP>exp</UP>[2<UP>ln</UP>C<SUB>0</SUB>+2&sfgr;(r<SUP>2</SUP>/2−r<SUP>2</SUP><SUB>0</SUB>/2)+<UP>ln</UP>K]
where C is the CRP concentration observed at radial position r, Delta C is the base-line offset, C0 is the concentration of CRP at the meniscus (r0), K is the dimer equilibrium association constant, and sigma  is the reduced molecular weight given by sigma  = Mr(1 - <A><AC>v</AC><AC>&cjs1171;</AC></A>rho )omega 2/2RT, where Mr is the monomer molecular weight, <A><AC>v</AC><AC>&cjs1171;</AC></A> is the partial specific volume, rho  is the solution density, omega  is the angular velocity, and R and T are the gas constant and the temperature in Kelvin, respectively.

Denaturation of CRP-- The effect of amino acid substitutions on the folding and domain-domain interactions in CRP was probed by monitoring the unfolding of CRP by GuHCl using fluorescence anisotropy. A detailed description of the protocol has been published (29). Briefly, the denaturation of CRP can best be described by a three-state model,
N<SUB>2</SUB> <LIM><OP><ARROW>⇄</ARROW></OP><UL>K<SUB>d</SUB></UL></LIM> 2N <LIM><OP><ARROW>⇄</ARROW></OP><UL>K<SUB>u</SUB></UL></LIM> 2U
<UP><SC>Reaction</SC> 1</UP>
in which N2, N, and U are folded dimer, folded monomer, and unfolded monomer of CRP, respectively. Kd and Ku are the equilibrium constants of dissociation and unfolding, respectively.

Unlike wild type CRP, mutant S128A/G141Q exhibits a weakened subunit association, which leads to a complete uncoupling of dimer dissociation and monomer unfolding. Therefore, these two processes can be studied separately. Subunit association of S128A/G141Q was measured by sedimentation equilibrium as described above. CRP unfolding was monitored by fluorescence anisotropy at the excitation and emission wavelengths of 280 and 345 nm, respectively.

To determine the equilibrium constant of unfolding, the fraction of CRP protein that is in the folded state, f , was calculated by the equation,
f=<FR><NU>(&egr;−&egr;<SUB><UP>unfolded</UP></SUB>)</NU><DE>(&egr;<SUB><UP>folded</UP></SUB>−&egr;<SUB><UP>unfolded</UP></SUB>)</DE></FR> (Eq. 5)
where epsilon , epsilon folded, and epsilon unfolded represent the measured fluorescence anisotropy signal of the protein sample and the values of fluorescence anisotropy of folded and unfolded monomer CRP at a given GuHCl concentration, respectively. epsilon folded and epsilon unfolded at the unfolding transition zone were derived by linear extrapolation of the measured signals at the predenaturation and postdenaturation zones, respectively.

Once f  was determined, the equivalent Ku at different GuHCl concentrations can be calculated as follows.
K<SUB>u</SUB>=<FR><NU>[<UP>U</UP>]</NU><DE>[<UP>N</UP>]</DE></FR>=<FR><NU>1−f</NU><DE>f</DE></FR> (Eq. 6)
Ku values were converted to Delta Gu by Delta Gu = -RTlnKu. Delta Gu0, the free energy of unfolding in the absence of denaturant, was subsequently determined by linear extrapolation of Delta Gu to zero denaturant (35).

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

In Vivo Genetic Characterization of CRP Mutants-- G141Q displayed purple colonies on MacConkey plates in the absence of external cAMP and in the presence of cGMP as reported earlier (15, 19, 36, 37). Thus, this mutant is characterized by a CRP* phenotype. Interestingly, while the S128A mutant showed a CRP- phenotype (18), the double mutant S128A/G141Q is a CRP* mutant in vivo. This in vivo observation indicates that mutation of G141Q exerts a dominant effect over mutation S128A.

In Vitro Structural Characterization of the S128A/G141Q Mutant

Near- and Far-UV CD-- Near- and far-UV CD spectra of the double mutant, S128A/G141Q are identical to that of the wild type CRP and S128A and G141Q single mutants (Fig. 1). These results indicate that no major secondary or tertiary structural changes have been introduced in CRP by these mutations.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 1.   CD spectra of the G141Q (open circle ), wild type CRP (bullet ), S128A/G141Q (down-triangle), and S128A (black-down-triangle ) in buffer A. Inset, CD signals of the wild type CRP (long dashed line), G141Q (solid line), S128A (short dashed line), and S128A/G141Q (medium dashed line) at the near-UV region. The axes of the inset and the rest of the figure are the same.

Subunit Association-- Like the wild type, S128A, and G141Q CRPs, the S128A/G141Q mutant exists in solution as an apparent dimer in the mg/ml concentration regime. However, one way of probing the effect of mutation on intersubunit communication is by monitoring the energetics of dimer formation of each mutant. Sedimentation equilibrium experiments of S128A/G141Q at different concentrations of GuHCl ranging from 0 to 1.5 M were conducted to determine the dimer dissociation constant for this double mutant. The sedimentation equilibrium experiments were performed at multiple speeds of 20,000, 28,000, and 34,000 rpm for each GuHCl concentration. The results are shown in Fig. 2A. The experimental data were then analyzed to estimate the apparent dimer association constant, Ka, app at each individual GuHCl concentration using the program NONLIN (38). A plot of LnKa, app versus GuHCl concentration displays an apparent linear relationship. Extrapolation of the data to zero concentration of GuHCl yields a value of the dimer association constant for S128A/G141Q in buffer (Fig. 2B). The extrapolated dimer association constant is similar to that of the G141Q mutant, i.e. weaker dimerization than that of the S128A mutant and wild type CRP. Table I summarized the results on subunit dissociation for all of the mutants and wild type CRP. Again, G141Q mutation exerts a dominating effect on subunit assembly.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 2.   Subunit association of S128A/G141Q studied by sedimentation equilibrium. A, sedimentation equilibrium profiles of S128A/G141Q at different angular velocity at 0 M GuHCl concentration. open circle , 34,000 rpm; square , 28,000 rpm; triangle , 20,000 rpm. The solid lines represent the best fits of the experimental data to Eq. 4. B, apparent dimer equilibrium association constants (determined from A) as a function of GuHCl concentration.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Parameters for subunit dissociation and protein stability of the wild type and mutant CRP

Protein Stability-- Protein stability studies in general can provide information on the folding stability of protein molecules and possibly domain-domain interaction. The stability of the double mutant was monitored by GuHCl denaturation studies using a published procedure (29). The unfolding curve of the S128A/G141Q mutant is characterized by a biphasic transition resembling that of the G141Q mutant, as shown in Fig. 3A. Again this reflects the uncoupling of the processes of dimer dissociation and monomer unfolding. Similarly, the unfolding free energy of the S128A/G141Q monomer was determined to be 7.4 kcal/mol, as shown in Fig. 3B. This value is similar to that of the wild type, S128A, and G141Q CRPs (Table I).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 3.   GuHCl-induced chemical denaturation of S128A/G141Q. A, denaturation curve of S128A/G141Q (1 µM) measured by fluorescence anisotropy. B, apparent unfolding free energy of S128A/G141Q monomer as a function of GuHCl concentration.

Protease Sensitivity-- The proteolytic digestion pattern of wild type CRP is biphasic as a function of cAMP. An initial increase in the rate of proteolysis at low cAMP concentration was followed by a decrease in rate with a further increase in cAMP concentration (17). The S128A mutant shows a significant decrease in sensitivity to protease digestion in a wide range of cAMP concentrations (18), while mutant G141Q is sensitive to protease cleavage in the absence of cAMP. The digestion pattern of the S128A/G141Q double mutant is different from that of the wild type and S128A mutant but similar to that of the G141Q mutant (Fig. 4). The S128A/G141Q mutant is also susceptible to either chymotrypsin or subtilisin digestion in the absence of cAMP. The digestion rates of S128A/G141Q and G141Q CRP are dependent on cAMP concentration. Furthermore, the rate decreases in the order of increasing cAMP concentration. The effects of cGMP on the proteolytic digestion patterns of CRP and the mutants were also examined. At a low cGMP concentration (200 µM) no significant effect was observed, while at a high cGMP concentration (50 mM) the rate of protease digestion for both G141Q and S128A/G141Q CRP decreased significantly as compared with the unliganded protein (Fig. 4).


View larger version (52K):
[in this window]
[in a new window]
 
Fig. 4.   Proteolytic digestion of the wild type CRP, S128A, G141Q, and S128A/G141Q by chymotrypsin and subtilisin in the presence or absence of cAMP or cGMP. Lanes 1-5 show results with chymotrypsin. Lane 1, CRP alone; lanes 2 and 3, with 200 µM and 50 mM cAMP, respectively; lanes 4 and 5, with 200 µM and 50 mM cGMP, respectively. Lanes 6-10 are proteolytic results under the same experimental conditions as lanes 1-5 but in the presence of subtilisin.

In Vitro Functional Characterization of CRP Mutants

Cyclic Nucleotide Binding-- Unlike wild type CRP, mutant G141Q CRP can also be activated by cGMP and other cyclic nucleotides for specific DNA binding (19). Thus, the binding affinities of the G141Q mutant for cGMP and cAMP were determined by monitoring the fluorescence quenching of the IAF-labeled G141Q CRP as a function of cGMP concentration, and the results are shown in Fig. 5. The estimated values of the equilibrium binding constants for cGMP are k1 = 4.7 × 104 M-1 and k2 = 3.2 × 103 M-1 as listed in Table II. In comparison, equilibrium binding constants for cAMP are k1 = 6.4×104 M-1 and k2 = 2.5×103 M-1. Thus, the binding constants of cAMP and cGMP in the G141Q mutant are essentially identical.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 5.   Binding of cAMP (open circle ) and cGMP (bullet ) to the G141Q mutant as monitored by fluorescence quenching of G141Q-IAF complex. The solid lines represent the best fits of the data to Eq. 1.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Summary of fitted parameters for cyclic nucleotide binding to CRP mutants

cAMP binding to S128A/G141Q CRP was monitored by fluorescence quenching of the S128A/G141Q-IAF complex (Fig. 6). Values of 1.4×104 M-1 and 1.9×102 M-1 were determined for k1 and k2, respectively. The binding constant of the first cAMP is slightly lower than but not significantly different from that of wild type, S128A, and G141Q CRP, whereas the binding constant for the second cAMP is about 6 and 14 times lower than that of wild type and G141Q CRP, respectively.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 6.   Binding of cAMP to S128A/G141Q as monitored by fluorescence quenching of S128A/G141Q-IAF. The solid lines represent the best fits of the data to Eq. 1.

Negative cooperativity in cAMP binding has been observed in wild type CRP (17), and the ratio of the microscopic cAMP binding constants, k1 and k2, can be used to estimate the degree of cooperativity. For the wild type and G141Q CRPs, values of about 25 were determined (Table II), while the two binding constants differed more than 1000-fold in mutant S128A CRP, indicating that mutation at residue 128 leads to an even higher degree of negative cooperativity in CRP. Interestingly, a value of 74 for k1/k2 was observed for the double mutant. This result suggests that the strong negative cooperativity for cAMP binding observed in S128A is partially preserved in S128A/G141Q CRP.

DNA Binding-- cGMP binds to but fails to activate wild type CRP (21, 39). Interestingly, cGMP not only binds to G141Q CRP with affinity similar to cAMP, but it can also replace cAMP in activating G141Q CRP to interact with DNA (19). When cGMP was titrated into a solution containing 13 nM lac-40-CPM DNA and 1 µM of G141Q CRP, the formation of a protein-DNA complex responded to the increase of cGMP concentration in a biphasic manner that is similar to the response of wild type CRP to cAMP (Fig. 7A). This biphasic behavior reflects the strong affinity of CRP-cGMP1 for lac-40 DNA but a decreased affinity of the CRP-cGMP2 species. Quantitative determination of the apparent binding constant of G141Q CRP to DNA in the presence of 100 µM cGMP yields a value of 3.0 × 107 M-1 (Fig. 7B), while wild type CRP binds to specific DNA with an apparent binding constant of less than 7 × 104 M-1 (Table III). Such high affinity of G141Q-cGMP1 complex for specific DNA is close to the affinity of CRP-cAMP1 complex to some naturally occurring CRP-dependent promoters, indicating a possible physiological significance, e.g. the activation of some CRP-dependent promoters in the absence of cAMP.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 7.   Interaction of G141Q with lac-40 DNA in the presence of cGMP. A, G141Q-DNA interaction as a function of cGMP concentration. B, binding of G141Q to lac-40 DNA in the presence of 100 µM cGMP. The solid line represents the best fit of the data to Eq. 2.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Apparent DNA binding affinity of the wild type and mutants in the presence of cAMP or cGMP
The experiments were performed in buffer A and 100-200 µM cAMP or cGMP.

The binding of S128A/G141Q CRP to lac-40-CPM-labeled DNA in the presence of cAMP was also studied (Fig. 8). The apparent DNA binding constant of S128A/G141Q CRP in the presence of 200 µM cAMP is 1.7 × 107 M-1, which is stronger than that of S128A CRP but weaker than that of G141Q CRP. cGMP can also activate S128A/G141Q CRP for specific DNA binding (Fig. 8). The estimated apparent DNA binding constant of S128A/G141Q CRP in the presence of cGMP is about 3.0 × 106 M-1. Under the same conditions, S128A CRP has no measurable binding affinity to lac-40 DNA.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 8.   Binding of the S128A/G141Q to lac-40 DNA in the presence of 200 µM cAMP (square ) and 200 µM cGMP (open circle ). The solid lines represent the best fit of the data to Eq. 2.

When the DNA binding constants for CRP in the presence of cAMP or cGMP are compared, a more than 5,000-fold difference is obtained (Table III), suggesting that CRP is highly selective for cyclic nucleotides. Mutation S128A does not seem to affect the selectivity, while mutation G141Q leads to a dramatic relaxation in cyclic nucleotide selectivity, decreasing the 5,000-fold difference in binding affinity to only about 8-fold. Moreover, the effect of the G141Q mutation is preserved in the double mutant (Table III). These results imply that the G141Q mutation exhibits a dominant effect over the S128A mutation in conferring recognition to specific DNA sequence and discriminatory ability toward the various cyclic nucleotides.

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

In vitro studies of CRP-DNA interaction show that the species that interacts with specific DNA sequences is CRP-cAMP1 (17, 18, 20, 26, 28, 40, 41). The CRP-cAMP2 complex exhibits much lower or no affinity for these DNA sequences. There is no exception for all of the nine DNA fragments of natural or artificial sequences studied (28, 41). One possible rationale for this behavior is the requirement of recognition between two asymmetric macromolecules, namely CRP-cAMP1 and CRP-dependent promoter, as proposed by Heyduk and Lee (17). The natural DNA sequences of CRP binding sites are not palindromic (1, 3), and RNA polymerase seems to recognize a DNA-bound CRP subunit in a particular orientation (42, 43). Hence, it is conceivable that CRP binds to the asymmetric DNA site in a specific orientation. Binding of one cAMP molecule to the dimeric CRP molecule would render the protein molecule asymmetric. If the functional mode of CRP is the assumption of an asymmetric structure by binding of one cAMP molecule, then it is imperative that the CRP-cAMP2 species does not form readily. The negatively cooperative binding of cAMP to CRP is apparently designed to achieve such a goal. If such an interpretation is valid, then what are the structural elements in the CRP molecule that impart these functional properties? What is the relation between these elements? Are they cooperative or antagonistic? Does one element exert a dominant effect over another? Results of this study indicate that residues 128 and 141 exhibit dominant effects on different functional properties of CRP.

Role of Residue 128 and C-helix in the Negative Cooperativity of cAMP Binding-- An earlier study on cAMP binding to alpha -CRP, the ligand binding domain of CRP generated by proteolytic digestion, led to the observation that the degree of negative cooperativity in cAMP binding is related to the amount of C-helix retained in alpha -CRP (25). Retention of the complete C-helix leads to a alpha -CRP molecule that binds only one cAMP, i.e. the degree of negative cooperativity is so great that it prevents occupation of the second site. Conversely, elimination of the C-helix leads to an abolishment of negative cooperativity so that both sites can bind cAMP with the same affinity. These results imply a possible role for C-helix in imparting negative cooperativity in CRP. Based on the crystallographic data of CRP, serine 128 occupies an important position in the C-helix (4, 44). Results show that mutations of serine 128 do not affect the affinity of the binding of the first cAMP molecule; however, the degree of negative cooperativity is greater (18). Thus, results of studying site-directed and deletion mutants implicate the C-helix in CRP in an important role in imparting negative cooperativity in cAMP binding to CRP.

The linkage between the C-helix and negative cooperativity is further strengthened by the results for the G141Q mutant. Residue 141 does not reside in the C-helix. The ligand binding properties of wild type CRP are quantitatively retained by the G141Q mutant, namely the same degree of negative cooperativity and same affinities for either cAMP or cGMP. Thus, mutating residue 141 apparently does not perturb the functional properties of the cAMP binding domain except to weaken the interaction along the subunit interface. In addition, the effect of the S128A mutation on negative cooperativity of cAMP binding is partially retained in the double mutant S128A/G141Q. The results of this study of a limited number of mutants indicate that the C-helix apparently plays an important role in imparting negative cooperativity in cAMP binding to CRP and that residue 128 apparently exhibits a dominant effect over residue 141 in maintaining negative cooperativity in ligand binding.

Role of Residue 141 and Subunit Interface in the Discrimination of Cyclic Nucleotides-- Another important issue in the mechanism of CRP function is its ability to bind and be activated only by cAMP. Although other cyclic nucleotides can bind to CRP, no activation in CRP toward recognition of specific DNA sequence is observed. Nevertheless, the G141Q mutant provides an opportunity to address the issue of cyclic nucleotide discrimination. The strict specificity requirement for cyclic nucleotide observed in wild type CRP is significantly relaxed in the G141Q mutant (19) as well as in the double mutant S128A/G141Q. These observations are unexpected. One may speculate that specificity will be imparted by amino acid residues within the binding site of cyclic nucleotides. Serine 128 resides in the cAMP domain and is a prime candidate for discriminating specific cyclic nucleotides, since the crystallographic data indicate hydrogen bonding between the hydroxyl group of serine 128 and N-6 of cAMP (4). However, elimination of the hydroxyl group by a Ser right-arrow Ala substitution does not affect the ability of the S128A mutant to discriminate between cAMP and cGMP. Yet, a substitution of glycine by glutamine in residue 141, which is neither located within the cAMP binding domain nor involved in the formation of intersubunit contacts, leads to a breakdown in the ability of CRP to discriminate cAMP from the other cyclic nucleotides.

Substitution of Gly right-arrow Gln does not lead to any change in the secondary or tertiary structure of CRP as monitored by CD, and this substitution does not alter the global folding of CRP as monitored by chemical denaturation (20, 45). Thus, spectroscopically and energetically, a Gly right-arrow Gln mutation does not produce any significant perturbation in the structure of CRP, and the loss of ability to discriminate cyclic nucleotides is not the result of detectable alteration in the global structure of CRP. Mutation G141Q results in a weakening in the energetics of intersubunit interaction. The consequence is an increase in susceptibility to protease digestion along the C-helices, an observation that mimics the effect of cAMP binding. The net result of this weaker interfacial interaction is a relaxation of cyclic nucleotide discrimination. Therefore, CRP maintains its cyclic nucleotide selectivity by imposing an energetic barrier along the subunit interface that only cAMP can overcome. Interestingly, the double mutant S128A/G141Q responds to protease digestion in a manner almost identical to the G141Q. This result can be interpreted to imply that the structural changes along the subunit interface introduced by the G141Q mutation can override the local structural changes created by the S128A mutation.

Role of Domain Interface in CRP Activation-- A combination of subunit realignment and domain rearrangement activates CRP for specific DNA binding. The G141Q mutation only leads to a change in realignment of subunits without inducing the proper domain rearrangement. The latter structural change is only induced upon binding of cyclic nucleotide. That is the underlying reason why the G141Q mutant cannot bind to a specific DNA sequence without cAMP. The supporting evidence for this interpretation is the response of the IAF-labeled G141Q CRP to the titration of cAMP or cGMP. The IAF is covalently attached to cysteine 178, which is located at a position just before the DNA-binding helix (F-helix). Quenching of fluorescence intensity of the covalently attached fluorescein probe was observed and must reflect the domain rearrangement in response to ligand binding. The estimated values of binding constants are in good agreement with the values determined by other approaches. This again suggests that the cAMP- or cGMP-induced fluorescence quenching reflects the intrinsic conformational changes in the DNA binding domain in response to cAMP or cGMP binding. The IAF-labeled S128A/G141Q CRP responds to the binding of cAMP in a manner similar to that of G141Q CRP. This effect further substantiates the involvement of domain-domain rearrangement in CRP activation by cAMP and the dominating effect of the G141Q mutation.

In summary, the results from this study imply that the cyclic nucleotide-induced activation process is linked to the energetics of overcoming an unfavorable intersubunit structure. A weaker interfacial interaction, such as those observed in the G141Q and S128A/G141Q mutants, makes it easier to switch over to the appropriate intersubunit structure and consequently to induce the proper interdomain orientation for specific DNA sequence recognition. Furthermore, this study reveals the apparent dominant effects of residues 128 and 141 in conferring functional characteristics in CRP. The influence of residue 128 is more significant in ligand binding (in particular, binding of the second cAMP). Residue 141 exerts more effects on the energetics of dimerization and all events apparently associated with intersubunit interactions, e.g. discrimination among various cyclic nucleotides in their ability to activate CRP for binding to specific DNA sequence.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant GM-45579 and Robert A. Welch Foundation Grants H-0013 and H-1238.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Present address: Dept. of Chemistry and Biochemistry, University of California at San Diego, La Jolla, CA 92093-0654.

§ To whom correspondence should be addressed.

1 The abbreviations used are: CRP, cAMP receptor protein; CPM, 7-diethylamine-3-(4'-maleimidylphenyl)-4-methylcoumarin; GuHCl, guanidine hydrochloride; IAF, iodoacetamidofluorescein.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

  1. de Crombrugghe, B., Busby, S., and Buc, H. (1984) Science 224, 831-838[Medline] [Order article via Infotrieve]
  2. Botsford, J. L., and Harman, J. G. (1992) Microbiol. Rev. 56, 100-122[Abstract]
  3. Kolb, A., Busby, S., Buc, H., Garge, S., and Adhya, S. (1993) Annu. Rev. Biochem. 62, 749-795[CrossRef][Medline] [Order article via Infotrieve]
  4. Weber, I. T., and Steitz, T. A. (1987) J. Mol. Biol. 198, 311-326[Medline] [Order article via Infotrieve]
  5. Krakow, J. S., and Pastan, I. (1973) Proc. Natl. Acad. Sci. U. S. A. 70, 2529-2533[Abstract]
  6. Wu, F. Y-H., Nath, K., and Wu, C.-W. (1974) Biochemistry 13, 2567-2572[Medline] [Order article via Infotrieve]
  7. Wu, C.-W., and Wu, F. Y.-H. (1974) Biochemistry 13, 2573-2578[Medline] [Order article via Infotrieve]
  8. Eilen, E., and Krakow, J. S. (1977) J. Mol. Biol. 114, 47-60[Medline] [Order article via Infotrieve]
  9. Pampeno, C., and Krakow, J. S. (1979) Biochemistry 18, 1519-1525[Medline] [Order article via Infotrieve]
  10. Tsugita, A., Blazy, B., Takahashi, M., and Baudras, A. (1982) FEBS Lett. 144, 304-308[CrossRef]
  11. Lee, B. J., Lee, S. J., Hayashi, F., Aiba, H., and Kyogoku, Y. (1990) J. Biochem. (Tokyo) 107, 304-309[Abstract]
  12. Sixl, F., King, R. W., and Feeney, J. (1990) Biochem. J. 266, 545-552[Medline] [Order article via Infotrieve]
  13. Hinds, M. G., King, R. W., and Feeney, J. (1992) Biochem. J. 287, 627-632[Medline] [Order article via Infotrieve]
  14. Gronenborn, A. M., and Clore, G. M. (1982) Biochemistry 21, 4040-4048[Medline] [Order article via Infotrieve]
  15. Tan, G.-S., Kelly, P., Kim, J., and Wartell, R. M. (1991) Biochemistry 30, 5076-5080[Medline] [Order article via Infotrieve]
  16. Heyduk, E., Heyduk, T., and Lee, J. C. (1992) J. Biol. Chem. 267, 3200-3204[Abstract/Free Full Text]
  17. Heyduk, T., and Lee, J. C. (1989) Biochemistry 28, 6914-6924[Medline] [Order article via Infotrieve]
  18. Cheng, X., Kovac, L., and Lee, J. C. (1995) Biochemistry 34, 10816-10826[Medline] [Order article via Infotrieve]
  19. Cheng, X., and Lee, J. C. (1994) J. Biol. Chem. 269, 30781-30784[Abstract/Free Full Text]
  20. Cheng, X. (1994) Mechanism of Cyclic AMP Receptor Protein Activation by Cyclic AMP in Escherichia coli.Ph.D. dissertation, University of Texas Medical Branch, Galveston, TX
  21. Takahashi, M., Blazy, B., and Baudras, A. (1980) Biochemistry 19, 5124-5130[Medline] [Order article via Infotrieve]
  22. Merck & Co., Inc.. (1976) The Merck Index, 9th Ed., p. 353, Merck & Co., Inc., Rahway, NJ
  23. Sippel, T. O. (1981) J. Histochem. Cytochem. 29, 1377-1381[Abstract]
  24. Cerione, R. A., McCarty, R. E., and Hammes, G. G. (1983) Biochemistry 22, 769-776[Medline] [Order article via Infotrieve]
  25. Heyduk, E., Heyduk, T., and Lee, J. C. (1992) Biochemistry 31, 3682-3688[Medline] [Order article via Infotrieve]
  26. Heyduk, T., and Lee, J. C. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 1744-1748[Abstract]
  27. Heyduk, T., and Lee, J. C. (1992) Biochemistry 31, 5165-5171[Medline] [Order article via Infotrieve]
  28. Pyles, E. A., and Lee, J. C. (1996) Biochemistry 35, 1162-1172[CrossRef][Medline] [Order article via Infotrieve]
  29. Cheng, X., Gonzalez, M., and Lee, J. C. (1993) Biochemistry 32, 8130-8139[Medline] [Order article via Infotrieve]
  30. Yphantis, D. A. (1964) Biochemistry 3, 297-317
  31. Aiba, H., Fujimoto, S., and Ozaki, N. (1982) Nucleic Acids Res. 10, 1345-1361[Abstract]
  32. Cossart, P., and Gicquel-Sanzey, B. (1982) Nucleic Acids Res. 10, 1363-1378[Abstract]
  33. Cohn, E. J., and Edsall, J. T. (1943) Proteins, Amino Acids and Peptides, p. 372, Van Nostrand-Reinhold, Princeton, NJ
  34. Lee, J. C., and Timasheff, S. N. (1979) Methods Enzymol. 61, 49-57[Medline] [Order article via Infotrieve]
  35. Pace, C. N., Shirley, B. A., and Thomson, J. A. (1989) in Protein Structure: A Practical Approach (Creighton, T. E., ed), pp. 311-330, IRL Press, New York, NY
  36. Sanders, R., and McGeoch, D. (1973) Proc. Natl. Acad. Sci. U. S. A. 70, 1017-1021[Abstract]
  37. Kim, J., Adhya, S., and Garges, S. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 9700-9704[Abstract]
  38. Johnson, M. L., Correia, J. J., Yphantis, D. A., Halvorson, H. R. (1981) Biophys. J. 36, 575-588[Abstract]
  39. Riggs, A. D., Reiness, G., and Zubay, G. (1971) Proc. Natl. Acad. Sci. U. S. A. 68, 1222-1225[Abstract]
  40. Fried, M., and Crothers, D. M. (1984) J. Mol. Biol. 172, 241-262[Medline] [Order article via Infotrieve]
  41. Pyles, E. A., and Lee, J. C. (1994) Biophys. J. 66, A370
  42. Zhou, Y., Busby, S., and Ebright, R. H. (1993) Cell 73, 375-379[Medline] [Order article via Infotrieve]
  43. Zhou, Y., Pendergrast, P. S., Bell, A., Williams, R., Busby, S., and Ebright, R. H. (1994) EMBO J. 13, 4549-4557[Abstract]
  44. McKay, D. B., Weber, I. T., and Steitz, T. A. (1982) J. Biol. Chem. 257, 9518-9524[Abstract/Free Full Text]
  45. Cheng, X., and Lee, J. C. (1998) Biochemistry, in press


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.